@article{270b570af0d64a6d94c0c0cc127eaa7a,
title = "Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA",
author = "Rich, \{Nicole E.\} and Mazen Noureddin and Fasiha Kanwal and Singal, \{Amit G.\}",
note = "Funding Information: MN has been on the advisory board for 89BIO, Gilead, Intercept, Pfizer, Novartis, Novo Nordisk, Allergan, Blade, EchoSens, Fractyl, Terns, OWL, Siemens, Roche Diagnostic, and Abbott; has received research support from Allergan, Bristol Myers Squibb, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Pfizer, Madrigal, Novartis, Shire, Viking{\textquoteright} and Zydus; and is a minor shareholder or has stocks in Anaetos, Rivus Pharma, and Viking. FK reports grants from Merck and Gilead. AGS has been on advisory boards and served as a consultant for Wako Diagnostics, Roche, Exact Sciences, Glycotest, Bayer, Eisai, Exelixis, Bristol Myers Squibb, AstraZeneca, Genentech, and TARGET-RWE. NER declared no competing interests.",
year = "2021",
month = jun,
doi = "10.1016/S2468-1253(21)00100-X",
language = "English (US)",
volume = "6",
pages = "422--424",
journal = "The Lancet Gastroenterology and Hepatology",
issn = "2468-1253",
publisher = "Elsevier Ltd",
number = "6",
}